Q4 Earnings Forecast for Insulet Issued By Leerink Partnrs

Insulet Co. (NASDAQ:PODDFree Report) – Investment analysts at Leerink Partnrs lowered their Q4 2024 earnings estimates for Insulet in a research note issued on Thursday, November 7th. Leerink Partnrs analyst M. Kratky now forecasts that the medical instruments supplier will post earnings per share of $0.99 for the quarter, down from their prior estimate of $1.00. The consensus estimate for Insulet’s current full-year earnings is $3.10 per share. Leerink Partnrs also issued estimates for Insulet’s Q2 2025 earnings at $0.88 EPS, Q3 2025 earnings at $1.15 EPS, Q4 2025 earnings at $1.22 EPS, FY2027 earnings at $6.46 EPS and FY2028 earnings at $7.75 EPS.

A number of other brokerages have also recently issued reports on PODD. UBS Group increased their target price on shares of Insulet from $211.00 to $223.00 and gave the company a “neutral” rating in a report on Friday, August 9th. BTIG Research raised their price objective on shares of Insulet from $260.00 to $270.00 and gave the stock a “buy” rating in a research note on Friday, November 8th. Raymond James raised their price objective on shares of Insulet from $213.00 to $260.00 and gave the stock an “outperform” rating in a research note on Monday, October 14th. Sanford C. Bernstein started coverage on shares of Insulet in a research note on Wednesday, November 6th. They set an “outperform” rating and a $300.00 price objective for the company. Finally, Piper Sandler raised their price objective on shares of Insulet from $230.00 to $285.00 and gave the stock an “overweight” rating in a research note on Tuesday, September 17th. Three investment analysts have rated the stock with a hold rating and twelve have given a buy rating to the stock. According to MarketBeat.com, Insulet has a consensus rating of “Moderate Buy” and an average price target of $253.27.

Check Out Our Latest Stock Analysis on PODD

Insulet Trading Down 0.2 %

Shares of Insulet stock opened at $275.10 on Monday. Insulet has a 12-month low of $156.00 and a 12-month high of $279.40. The company has a current ratio of 3.60, a quick ratio of 2.71 and a debt-to-equity ratio of 1.36. The stock has a market cap of $19.29 billion, a PE ratio of 47.11, a price-to-earnings-growth ratio of 5.00 and a beta of 1.22. The company has a 50-day moving average of $234.83 and a two-hundred day moving average of $206.03.

Hedge Funds Weigh In On Insulet

A number of hedge funds have recently made changes to their positions in PODD. Blue Trust Inc. boosted its holdings in shares of Insulet by 84.1% in the 3rd quarter. Blue Trust Inc. now owns 127 shares of the medical instruments supplier’s stock valued at $30,000 after purchasing an additional 58 shares during the last quarter. International Assets Investment Management LLC acquired a new position in shares of Insulet during the 2nd quarter valued at $32,000. Venturi Wealth Management LLC lifted its holdings in shares of Insulet by 633.3% during the 3rd quarter. Venturi Wealth Management LLC now owns 154 shares of the medical instruments supplier’s stock valued at $36,000 after acquiring an additional 133 shares in the last quarter. UMB Bank n.a. lifted its holdings in shares of Insulet by 81.0% during the 2nd quarter. UMB Bank n.a. now owns 181 shares of the medical instruments supplier’s stock valued at $37,000 after acquiring an additional 81 shares in the last quarter. Finally, CVA Family Office LLC lifted its holdings in shares of Insulet by 138.1% during the 2nd quarter. CVA Family Office LLC now owns 250 shares of the medical instruments supplier’s stock valued at $50,000 after acquiring an additional 145 shares in the last quarter.

Insulet Company Profile

(Get Free Report)

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.

Featured Stories

Earnings History and Estimates for Insulet (NASDAQ:PODD)

Receive News & Ratings for Insulet Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Insulet and related companies with MarketBeat.com's FREE daily email newsletter.